Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.01638-18. doi: 10.1128/AAC.01638-18. [Epub ahead of print]

PMID:
30642925
2.

Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.

Badée J, Qiu N, Parrott N, Collier AC, Schmidt S, Fowler S.

Drug Metab Dispos. 2019 Feb;47(2):124-134. doi: 10.1124/dmd.118.084301. Epub 2018 Nov 26.

PMID:
30478159
3.

Screening Pregnant Women and Their Neonates for Illicit Drug Use: Consideration of the Integrated Technical, Medical, Ethical, Legal, and Social Issues.

Price HR, Collier AC, Wright TE.

Front Pharmacol. 2018 Aug 28;9:961. doi: 10.3389/fphar.2018.00961. eCollection 2018. Review.

4.

Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.

Kallianpur AR, Gittleman H, Letendre S, Ellis R, Barnholtz-Sloan JS, Bush WS, Heaton R, Samuels DC, Franklin DR Jr, Rosario-Cookson D, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, McCutchan JA, Morgello S, Grant I, Simpson D, Connor JR, Hulgan T; CHARTER Study Group.

Mol Neurobiol. 2018 Sep 12. doi: 10.1007/s12035-018-1329-9. [Epub ahead of print]

PMID:
30209774
5.

Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.

Kiang TKL, Partovi N, Shapiro RJ, Berman JM, Collier AC, Ensom MHH.

Clin Drug Investig. 2018 Nov;38(11):1011-1022. doi: 10.1007/s40261-018-0694-5.

PMID:
30178220
6.

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.

Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY.

AIDS. 2018 Nov 13;32(17):2463-2467. doi: 10.1097/QAD.0000000000001969.

PMID:
30102655
7.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

PMID:
30085241
8.

Detection of opioids in umbilical cord lysates: an antibody-based rapid screening approach.

Knight SJ, Smith AD, Wright TE, Collier AC.

Toxicol Mech Methods. 2018 Jul 31:1-26. doi: 10.1080/15376516.2018.1506850. [Epub ahead of print]

PMID:
30064290
9.

The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.

Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N.

Clin Pharmacokinet. 2019 Feb;58(2):189-211. doi: 10.1007/s40262-018-0681-2. Review.

PMID:
29862468
10.

No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Stekler JD, Tapia K, Maenza J, Stevens CE, Ure GA, O'Neal JD, Lane A, Mullins JI, Coombs RW, Holte S, Collier AC.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):657-666. doi: 10.1089/AID.2017.0276. Epub 2018 Jun 13.

PMID:
29756456
11.

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.

Stekler JD, Milne R, Payant R, Beck I, Herbeck J, Maust B, Deng W, Tapia K, Holte S, Maenza J, Stevens CE, Mullins JI, Collier AC, Frenkel LM.

PLoS Med. 2018 Mar 27;15(3):e1002537. doi: 10.1371/journal.pmed.1002537. eCollection 2018 Mar.

12.

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY.

J Pharm Sci. 2018 Jul;107(7):1787-1790. doi: 10.1016/j.xphs.2018.03.005. Epub 2018 Mar 13.

PMID:
29548975
13.

Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals.

Manuzak JA, Gott TM, Kirkwood JS, Coronado E, Hensley-McBain T, Miller C, Cheu RK, Collier AC, Funderburg NT, Martin JN, Wu MC, Isoherranen N, Hunt PW, Klatt NR.

Clin Infect Dis. 2018 Jun 1;66(12):1872-1882. doi: 10.1093/cid/cix1116.

PMID:
29471387
14.

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Sun J, Collier AC, Collins C, Shen DD, Ho RJY.

J Control Release. 2018 Apr 10;275:229-241. doi: 10.1016/j.jconrel.2018.02.003. Epub 2018 Feb 10.

PMID:
29432823
15.

Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings.

Torres TS, Harrison LJ, La Rosa AM, Lavenberg JA, Zheng L, Safren SA, Ngongondo M, Poongulali S, Matoga M, Samaneka W, Collier AC, Hughes MD.

AIDS Care. 2018 Aug;30(8):954-962. doi: 10.1080/09540121.2018.1427207. Epub 2018 Jan 18.

PMID:
29343078
16.

Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women.

Torres TS, Harrison LJ, La Rosa AM, Cardoso SW, Zheng L, Ngongondo M, Some F, Lalloo UG, Mwelase T, Collier AC, Hughes MD; AIDS Clinical Trials Group (ACTG) A5273 Study Group.

AIDS. 2018 Mar 13;32(5):583-593. doi: 10.1097/QAD.0000000000001738.

PMID:
29334547
17.

Regulation of Hepatic UGT2B15 by Methylation in Adults of Asian Descent.

Oeser SG, Bingham JP, Collier AC.

Pharmaceutics. 2018 Jan 7;10(1). pii: E6. doi: 10.3390/pharmaceutics10010006.

18.

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.

Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, Schoffelen AF, Ciaffi L, Stafford K, Collier AC, Paton NI, Geretti AM.

Clin Infect Dis. 2018 Jun 1;66(12):1846-1857. doi: 10.1093/cid/cix1108.

19.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

20.

Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.

Smetana KS, Dunne J, Parrott K, Davis GA, Collier ACS, Covell M, Smyth S.

J Thromb Thrombolysis. 2017 Nov;44(4):519-524. doi: 10.1007/s11239-017-1560-7.

PMID:
28948507
21.

Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States.

Marquine MJ, Heaton A, Johnson N, Rivera-Mindt M, Cherner M, Bloss C, Hulgan T, Umlauf A, Moore DJ, Fazeli P, Morgello S, Franklin D, Letendre S, Ellis R, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Simpson D, McCutchan JA, Grant I, Heaton RK.

J Int Neuropsychol Soc. 2018 Feb;24(2):163-175. doi: 10.1017/S1355617717000832. Epub 2017 Sep 6.

22.

The effects of UDP-sugars, UDP and Mg2+on uridine diphosphate glucuronosyltransferase activity in human liver microsomes.

Walia G, Smith AD, Riches Z, Collier AC, Coughtrie MWH.

Xenobiotica. 2018 Sep;48(9):882-890. doi: 10.1080/00498254.2017.1376260. Epub 2017 Sep 26.

PMID:
28868965
23.

Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition.

Price HR, Collier AC.

Curr Pharm Des. 2017;23(40):6098-6114. doi: 10.2174/1381612823666170825123754.

PMID:
28847300
24.

Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.

Coban H, Robertson K, Smurzynski M, Krishnan S, Wu K, Bosch RJ, Collier AC, Ellis RJ.

AIDS. 2017 Jul 17;31(11):1565-1571. doi: 10.1097/QAD.0000000000001523.

25.

Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.

Jia P, Zhao Z, Hulgan T, Bush WS, Samuels DC, Bloss CS, Heaton RK, Ellis RJ, Schork N, Marra CM, Collier AC, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, McCutchan JA, Barnholtz-Sloan JS, Franklin DR, Rosario D, Letendre SL, Grant I, Kallianpur AR; CHARTER Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2017 Jun;174(4):413-426. doi: 10.1002/ajmg.b.32530. Epub 2017 Apr 26.

26.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team.

PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr.

27.

Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment.

Mehta SR, Pérez-Santiago J, Hulgan T, Day TR, Barnholtz-Sloan J, Gittleman H, Letendre S, Ellis R, Heaton R, Patton S, Suben JD, Franklin D, Rosario D, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur J, McCutchan A, Morgello S, Simpson D, Connor J, Grant I, Kallianpur A.

J Neuroinflammation. 2017 Mar 31;14(1):72. doi: 10.1186/s12974-017-0848-z.

28.

The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).

Riches Z, Liu Y, Berman JM, Walia G, Collier AC.

J Biochem Mol Toxicol. 2017 Aug;31(8). doi: 10.1002/jbt.21921. Epub 2017 Mar 27.

PMID:
28346733
29.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.

Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA.

Clin Infect Dis. 2017 Jun 1;64(11):1612-1614. doi: 10.1093/cid/cix176.

30.

Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.

Abanda NN, Riches Z, Collier AC.

Pharmaceutics. 2017 Feb 17;9(1). pii: E8. doi: 10.3390/pharmaceutics9010008.

31.

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ.

AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.

32.
33.

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Franklin DR, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Infect Dis. 2017 Jan 1;215(1):105-113. doi: 10.1093/infdis/jiw505. Epub 2016 Oct 26.

34.

Long-term body composition changes in antiretroviral-treated HIV-infected individuals.

Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, Erlandson KM, Lake JE, Yin MT, Melbourne K, Ha B, Brown TT.

AIDS. 2016 Nov 28;30(18):2805-2813.

35.

Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic" versus "asymptomatic" HAND.

Obermeit LC, Beltran J, Casaletto KB, Franklin DR, Letendre S, Ellis R, Fennema-Notestine C, Vaida F, Collier AC, Marra CM, Clifford D, Gelman B, Sacktor N, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2017 Feb;23(1):67-78. doi: 10.1007/s13365-016-0474-z. Epub 2016 Aug 24.

36.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

Grant PM, Kitch D, McComsey GA, Collier AC, Koletar SL, Erlandson KM, Yin MT, Bartali B, Ha B, Melbourne K, Brown TT.

J Infect Dis. 2016 Aug 15;214(4):607-11. doi: 10.1093/infdis/jiw204. Epub 2016 Jun 20.

37.

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC; ACTG A5273 Study Group.

Lancet HIV. 2016 Jun;3(6):e247-58. doi: 10.1016/S2352-3018(16)30011-X. Epub 2016 Apr 18.

38.

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals.

Cooley SA, Paul RH, Fennema-Notestine C, Morgan EE, Vaida F, Deng Q, Chen JA, Letendre S, Ellis R, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Ances BM; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2016 Oct;22(5):607-614. Epub 2016 Mar 28.

39.

A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.

Collier AC, Chun TW, Maenza J, Coombs RW, Tapia K, Chang M, Stevens CE, Justement JS, Murray D, Stekler JD, Mullins JI, Holte SE.

Biores Open Access. 2016 Jan 1;5(1):15-21. doi: 10.1089/biores.2015.0038. eCollection 2016.

40.

The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1).

Rougée LR, Riches Z, Berman JM, Collier AC.

Drug Metab Dispos. 2016 Jul;44(7):967-74. doi: 10.1124/dmd.115.068650. Epub 2016 Feb 8.

41.

Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals.

De Boni RB, Zheng L, Rosenkranz SL, Sun X, Lavenberg J, Cardoso SW, Grinsztejn B, La Rosa A, Pierre S, Severe P, Cohn SE, Collier AC, Gross R.

Drug Alcohol Depend. 2016 Feb 1;159:174-80. doi: 10.1016/j.drugalcdep.2015.12.013. Epub 2015 Dec 24.

42.

Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.

Kallianpur AR, Wang Q, Jia P, Hulgan T, Zhao Z, Letendre SL, Ellis RJ, Heaton RK, Franklin DR, Barnholtz-Sloan J, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Grant I; CHARTER Study Group.

J Infect Dis. 2016 Apr 1;213(7):1065-73. doi: 10.1093/infdis/jiv754. Epub 2015 Dec 21.

43.

Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.

Fazeli PL, Moore DJ, Franklin DR, Umlauf A, Heaton RK, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor NC, Morgello S, Simpson DM, McCutchan JA, Grant I, Letendre SL.

Curr HIV Res. 2016;14(4):324-30.

44.

The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values.

Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM.

CNS Drugs. 2015 Dec;29(12):975-83. doi: 10.1007/s40263-015-0295-2. Review.

PMID:
26585875
45.

Methamphetamine, smoking, and gestational hypertension affect norepinephrine levels in umbilical cord tissues.

Collier AC, Sato BL, Milam KA, Wright TE.

Clin Exp Obstet Gynecol. 2015;42(5):580-5.

PMID:
26524802
46.

Editorial: Recent Advances in Developmental Drug Disposition.

Collier AC.

Drug Metab Lett. 2015;9(2):64. No abstract available.

PMID:
26517862
47.

BCRP protein levels do not differ regionally in adult human livers, but decline in the elderly.

Riches Z, Abanda N, Collier AC.

Chem Biol Interact. 2015 Dec 5;242:203-10. doi: 10.1016/j.cbi.2015.10.007. Epub 2015 Oct 14.

48.

Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.

Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC; ACTG 5234 team.

Lancet HIV. 2015 Jan;2(1):e12-9. doi: 10.1016/S2352-3018(14)00007-1. Epub 2014 Dec 11.

PMID:
26424232
49.

The Effects of Obesity on Drug Metabolism in Children.

Oeser SG, Rougee LR, Collier AC.

Drug Metab Lett. 2015;9(2):88-98. Review.

PMID:
26411468
50.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2016 Apr;22(2):170-8. doi: 10.1007/s13365-015-0382-7. Epub 2015 Sep 25.

Supplemental Content

Loading ...
Support Center